Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Theralase Technologies Inc. > Finally! Easy to parse data!
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(1035)
•••
Comment by enriquesuaveon May 03, 2022 12:48pm
236 Views
Post# 34651523

RE:RE:RE:RE:RE:Finally! Easy to parse data!

RE:RE:RE:RE:RE:Finally! Easy to parse data!


enriquesuave wrote:

You posted the chart of All treated patients which includes 1st set of 12 who were severely undertreated.  Data is still amazing IMO even with this group.  I was referring to the Optimized group.  The chart just under the one you posted  on Sedar.

 

prophetoffact wrote: Given the full stability of the Complete Responders from day 270 to 450 getting all the data at day 270 could pretty much seal the deal for all patients through day 450 with a high level of confidence. 

 

 

prophetoffact wrote: "The Best part is that in the Optimized group, they went from

April 5th:  at 180 days 40.7% CR and 18.5% PR= totals responders 59.2%

April 29  at 180 days  53% CR  and 24% PR= total responders 76%-77%"

The Complete Response rate also jumped from 23.7% to 39% at 270 days. The 23.7% Complete Response cohort also showed stability through 450 days. 


Patient
Assessment Visit		 Evaluable
Patients*		 Complete
Response (“CR”)		 Partial
Response (“PR”)		 Total Response
(CR + PR)
90 Days 35 49% 17% 66%
180 Days 30 47% 20% 67%
270 Days 23 39% 9% 48%
360 Days 21 24% 14% 38%
450 Days 21 24% 10% 34%

 




<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities